PLUS PHARMA
ActiveSummary
PLUS PHARMA has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€151,542) and a net result of -€1,825. Equity remains stable across the filed fiscal years (±1.9% per year). The computed 12-month bankruptcy probability is 0.9% (low).
History
Acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
02-02
NBB filing
Annual accounts filed
fiscal year 2025 · unclassified schema · 2 days late
2024
10-12
NBB filing
Annual accounts filed
fiscal year 2024 · unclassified schema
28-02
NBB filing
Annual accounts filed
fiscal year 2023 · unclassified schema · 28 days late
2023
30-01
NBB filing
Annual accounts filed
fiscal year 2022 · unclassified schema
2022
25-01
NBB filing
Annual accounts filed
fiscal year 2021 · unclassified schema
2020
14-12
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
10-01
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
28-02
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema · 28 days late
2018
03-02
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 3 days late
2017
27-02
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 27 days late
NBB filing
0 of 1 act read
About the unread acts
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.